Teddi Mellencamp Reveals She Consulted Her Oncologist About Using GLP‑1s
Teddi Mellencamp is opening up about a recent conversation with her oncologist amid her ongoing cancer treatment.
The Real Housewives of Beverly Hills alum shared that she consulted her doctor about going on GLP-1 medication on an episode of her podcast Two Ts in a Pod.
"I am a health and wellness coach who's dying of cancer," she began. "And because I gained weight from the steroids [from my treatment], because I'm getting bigger from the steroids, I asked my doctor if I could please have GLP-1s. And he was like, 'No!'"
Co-host, Tamra Judge, quipped, "I'm so sorry someone told you no, but I don't know that I'd listen!"
"I mean, I know people where I could get it," Mellencamp replied. "I have friends that do it." To which Judge said, "Well, I'm taking it tomorrow if you wanna start with me."
Mellencamp expressed her frustration with her doctor not allowing her to go on GLP-1s.
"Let me live, You tell me to live my best life, but I don't even get… Live your best life? Where are my GLP-1s?" she said.
Judge said that she believed Mellencamp's doctor refusing to prescribe her GLP-1 medication is a sign they believe she will make a full recovery.
I think maybe someone's lying," she said. "I don't think you're dying. Because [if you were dying,] he would've said, 'Oh, if that's what you want, sure! Take that, go do some coke, go snort whatever you want!'"
Mellencamp was diagnosed with stage 2 melanoma in 2022. In March 2025, she announced that the cancer had metastasized to her brain and lungs.
Last month, Mellencamp presented her father, John Mellencamp, with the Icon Award at the iHeartRadio Music Awards. She took the time to express how her father has supported her throughout her cancer battle.
"He stepped up, took control, fought for me, and pretty much changed my life, saved my life," she said while presenting him with the award.
Copyright 2026 The Arena Group, Inc. All Rights Reserved
This story was originally published April 24, 2026 at 9:18 AM.